S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:AMTX

Aemetis Stock Forecast, Price & News

$15.24
+0.22 (+1.46%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.47
$15.72
50-Day Range
$15.02
$22.44
52-Week Range
$2.22
$27.44
Volume
1.00 million shs
Average Volume
2.11 million shs
Market Capitalization
$506.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.28
30 days | 90 days | 365 days | Advanced Chart
Receive AMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.


Aemetis logo

About Aemetis

Aemetis, Inc. is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota. The India segment refers to the Kakinada plant, administrative offices in Hyderabad, and holding companies in Nevada and Mauritius. Its products include glycerin, ethanol, food and feed, biodiesel, and edible oils. The company was founded by Eric Armstrong McAfee in 2006 and is headquartered in Cupertino, CA.

Headlines

Aemetis (NASDAQ:AMTX) Trading Down 4.8%
December 2, 2021 |  americanbankingnews.com
Aemetis (NASDAQ:AMTX) Shares Gap Up to $18.76
December 1, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:AMTX
Employees
164
Year Founded
N/A

Sales & Book Value

Annual Sales
$165.56 million
Book Value
($3.97) per share

Profitability

Net Income
$-36.66 million
Pretax Margin
-33.29%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,380,000
Market Cap
$506.75 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/21/2022

MarketRank

Overall MarketRank

2.20 out of 5 stars

Oils/Energy Sector

115th out of 350 stocks

Industrial Organic Chemicals Industry

9th out of 22 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Aemetis (NASDAQ:AMTX) Frequently Asked Questions

Is Aemetis a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis
or view top-rated stocks.

How has Aemetis' stock price been impacted by Coronavirus (COVID-19)?

Aemetis' stock was trading at $0.6511 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMTX shares have increased by 2,240.7% and is now trading at $15.24.
View which stocks have been most impacted by COVID-19
.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Aemetis
.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) posted its quarterly earnings data on Thursday, November, 11th. The specialty chemicals company reported ($0.55) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.25. The specialty chemicals company had revenue of $49.90 million for the quarter, compared to analyst estimates of $54.23 million. During the same quarter in the prior year, the business posted ($0.59) EPS.
View Aemetis' earnings history
.

What price target have analysts set for AMTX?

8 Wall Street analysts have issued 1 year target prices for Aemetis' shares. Their forecasts range from $25.00 to $35.00. On average, they anticipate Aemetis' share price to reach $31.17 in the next twelve months. This suggests a possible upside of 104.5% from the stock's current price.
View analysts' price targets for Aemetis
or view top-rated stocks among Wall Street analysts.

Who are Aemetis' key executives?

Aemetis' management team includes the following people:
  • Eric Armstrong McAfee, Chairman & Chief Executive Officer
  • Todd A. Waltz, Chief Financial Officer, Secretary & Executive VP
  • Andrew B. Foster, Executive Vice President (LinkedIn Profile)
  • Sanjeev Gupta, President-Aemetis International

What other stocks do shareholders of Aemetis own?

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by a number of institutional and retail investors. Top institutional investors include Grantham Mayo Van Otterloo & Co. LLC (6.05%), BlackRock Inc. (5.77%), Millennium Management LLC (2.21%), Renaissance Technologies LLC (1.83%), Geode Capital Management LLC (1.45%) and Morgan Stanley (1.27%). Company insiders that own Aemetis stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Sanjeev Gupta and Todd Waltz.
View institutional ownership trends for Aemetis
.

Which institutional investors are selling Aemetis stock?

AMTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Caption Management LLC, OLD Mission Capital LLC, Deutsche Bank AG, California State Teachers Retirement System, Wolverine Trading LLC, and Advisor Group Holdings Inc.. Company insiders that have sold Aemetis company stock in the last year include Andrew B Foster, Francis P Barton, John R Block, Sanjeev Gupta, and Todd Waltz.
View insider buying and selling activity for Aemetis
or view top insider-selling stocks.

Which institutional investors are buying Aemetis stock?

AMTX stock was purchased by a variety of institutional investors in the last quarter, including Grantham Mayo Van Otterloo & Co. LLC, Schonfeld Strategic Advisors LLC, Millennium Management LLC, Wellington Management Group LLP, Goldman Sachs Group Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, and BlackRock Inc..
View insider buying and selling activity for Aemetis
or or view top insider-buying stocks.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $15.24.

How much money does Aemetis make?

Aemetis has a market capitalization of $506.75 million and generates $165.56 million in revenue each year. The specialty chemicals company earns $-36.66 million in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 164 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

Where are Aemetis' headquarters?

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at [email protected], or via fax at 408-252-8044.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.